insights_auto
Why is ADAPY up ၇.၁၄%?
Dive Deeperchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
၀.၀၃၀ US$
arrow_upward
+၇.၁၄%(+၀.၀၀၂၀) 1D
အောက် ၉, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
၀.၀၃ US$
High
၀.၀၃ US$
Low
၀.၀၃ US$
Mkt. cap
၇.၄၂ သန်း
Avg. vol.
၂.၀၇ သိန်း
Volume
၇.၇၄ သောင်း
52-wk high
၀.၂၄ US$
52-wk low
၀.၀၀ US$
Beta
၀.၇၅
Shares outstanding
၂၆.၅၁ ကုဋေ
No. of employees
၂၇၂
Open
၀.၀၃ US$
High
၀.၀၃ US$
Low
၀.၀၃ US$
Mkt. cap
၇.၄၂ သန်း
Avg. vol.
၂.၀၇ သိန်း
Volume
၇.၇၄ သောင်း
52-wk high
၀.၂၄ US$
52-wk low
၀.၀၀ US$
Beta
၀.၇၅
Shares outstanding
၂၆.၅၁ ကုဋေ
No. of employees
၂၇၂
News stories
From web sources and news partners
The Globe and Mail
·
ပြီးခဲ့သည့် ၁ နာရီ
BTQ Technologies (NASDAQ: BTQ) (CBOE CA: BTQ) Named Security Partner for MoonPay Korea Stablecoin Infrastructure
Yahoo Finance
·
ပြီးခဲ့သည့် ၂ နာရီ
Prediction: This Is What a $5,000 Investment in the Vanguard S&P 500 ETF (VOO) Will Be Worth by 2040
Simply Wall Street
·
ပြီးခဲ့သည့် ၁ နာရီ
October 2026s Top Blockchain Stocks To Improve Your Portfolio
Nasdaq
·
ပြီးခဲ့သည့် ၁ ရက်
WISeSat.Space Holdings Corp. Rings the Opening Bell
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR